[go: up one dir, main page]

KR20060033247A - Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor - Google Patents

Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor Download PDF

Info

Publication number
KR20060033247A
KR20060033247A KR1020040082247A KR20040082247A KR20060033247A KR 20060033247 A KR20060033247 A KR 20060033247A KR 1020040082247 A KR1020040082247 A KR 1020040082247A KR 20040082247 A KR20040082247 A KR 20040082247A KR 20060033247 A KR20060033247 A KR 20060033247A
Authority
KR
South Korea
Prior art keywords
magnesium
group
composition
alcohol
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020040082247A
Other languages
Korean (ko)
Inventor
곽용근
강형섭
은재순
소준노
Original Assignee
주식회사 원제네시스
곽용근
강형섭
은재순
소준노
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 원제네시스, 곽용근, 강형섭, 은재순, 소준노 filed Critical 주식회사 원제네시스
Priority to KR1020040082247A priority Critical patent/KR20060033247A/en
Publication of KR20060033247A publication Critical patent/KR20060033247A/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 포함하는 숙취의 예방 및 해소용 조성물, 및 기능성 주류에 관한 것이다.The present invention relates to a composition for preventing and eliminating hangovers, and functional liquor comprising one or more components selected from the group consisting of magnesium compounds and magnesium salts and salvia extract.

상기의 숙취의 예방 및 해소용 조성물은 알코올 및 아세트알데히드 대사를 촉진하고 간세포 및 위벽세포를 보호하여, 알코올의 부작용을 최소화시키며, 상기의 기능성 주류는 주류 복용시의 숙취를 최소화 하는 우수한 효과를 제공한다.

The composition for preventing and eliminating hangover promotes alcohol and acetaldehyde metabolism and protects hepatocytes and gastric parietal cells, thereby minimizing side effects of alcohol, and the functional alcoholic beverage provides an excellent effect of minimizing hangover when drinking alcoholic beverages. do.

마그네슘, 단삼, 숙취해소, 알코올, 아세트알데히드Magnesium, Salvia, Hangover, Alcohol, Acetaldehyde

Description

마그네슘 화합물 및/또는 마그네슘염과 단삼을 포함하는 숙취의 예방 및 해소용 조성물, 및 기능성 주류{Composition for prevention and relief of alcoholic hangover, and alcoholic liquors containing magnesium compound and/or magnesium salt and Salvia miltorrhiza Bunge} Composition for prevention and relief of alcoholic hangover, and alcoholic liquors containing magnesium compound and / or magnesium salt and Salvia miltorrhiza Bunge}             

도 1은 산화마그네슘과 단삼을 포함하는 조성물을 알코올에 혼합하여 쥐에게 경구투여 하였을 때 혈중 알코올 농도에 미치는 영향을 다른 투여군과 비교하여나타낸 것이다. Figure 1 shows the effect on the blood alcohol concentration when compared to the other administration group when the composition containing magnesium oxide and dansam mixed with alcohol orally administered to the rat.

도 2는 산화마그네슘과 단삼을 포함하는 조성물을 알코올에 혼합하여 쥐에게 경구투여 하였을 때 시간에 따른 혈중 알코올 농도의 변화를 나타낸 것이다 (M1:산화마그네슘 2 mg/kg + 단삼추출물 2mg/kg; M2: 산화마그네슘 10 mg/kg + 단삼추출물 2mg/kg). Figure 2 shows a change in blood alcohol concentration over time when orally administered to mice mixed with a composition comprising magnesium oxide and dansam (M1: magnesium oxide 2 mg / kg + 2 mg / kg salvia extract; M2 : Magnesium oxide 10 mg / kg + salvia extract 2 mg / kg).

도 3은 산화마그네슘과 단삼을 포함하는 조성물을 알코올에 혼합하여 쥐에게 경구투여 하였을 때 시간에 따른 혈중 아세트알데히드 농도의 변화를 나타낸 것이다(M1:산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg; M2: 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg). Figure 3 shows the change in acetaldehyde concentration of blood with time when orally administered to mice mixed with a composition containing magnesium oxide and salvia (M1: magnesium oxide 2 mg / kg + salvia extract 2 mg / kg M2: magnesium oxide 10 mg / kg + salvia extract 2 mg / kg).

도 4는 글루콘산 마그네슘과 단삼을 포함하는 조성물을 알코올에 혼합하여 쥐에게 경구투여 하였을 때 시간에 따른 혈중 알코올 농도의 변화를 나타낸 것이다(M: 글루콘산 마그네슘 10 mg/kg + 단삼추출물 2 mg/kg).
Figure 4 shows a change in the blood alcohol concentration with time when orally administered to mice mixed with a composition containing magnesium gluconate and salvia (M: magnesium gluconate 10 mg / kg + 2 mg / salvia extract kg).

본 발명은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 포함하는 숙취의 예방 및 해소용 조성물, 및 기능성 주류에 관한 것이다.
The present invention relates to a composition for preventing and eliminating hangovers, and functional liquor comprising one or more components selected from the group consisting of magnesium compounds and magnesium salts and salvia extract.

술은 인류가 오랫동안 이용해 온 것으로 인간 관계 도모, 스트레스 해소, 수면촉진, 신진 대사촉진 등 유효한 면이 있는 반면 과음을 계속하는 경우에는 간에 치명적인 질병을 유발시키고, 과다한 알코올은 체내에서 흡수 및 분해가 잘 이루어지지 않아 두통과 속쓰림을 가져온다. Alcohol has been used for a long time by humans, and it is effective in promoting relationships, relieving stress, promoting sleep, and promoting metabolism, but if excessive drinking continues, it causes fatal diseases in the liver, and excessive alcohol is easily absorbed and broken down by the body. It doesn't work, leading to headaches and heartburn.

술의 주성분은 에탄올인데 섭취하면 주로 간에서 알코올디히드로게나제(alcohol dehydrogenase)에 의해 대사되어 아세트알데히드로 전환되며, 더 대사가 진행되면 아세트알데히드디히드로게나제(acetaldehyde dehydrogenase)에 의해 탄산가스와 물로 분해된다. 보통 적당량의 음주시에는 이들 효소가 원활하게 작용하여 부작용이 별로 나타나지 않지만, 과음시에는 아세트알데히드가 축적되어 구토 및 두통 등 부작용을 일으킨다. The main component of alcohol is ethanol. When ingested, it is mainly metabolized by alcohol dehydrogenase in the liver and converted to acetaldehyde.As further metabolism progresses, acetaldehyde dehydrogenase causes Decomposes into water. Usually, when the appropriate amount of drinking these enzymes work smoothly and side effects do not appear very much, but when excessive drinking, acetaldehyde accumulates, causing side effects such as vomiting and headache.                         

애주가들은 음주 후의 후유증을 걱정하고 피하기 위해 여러가지 음료, 약품을 복용하기도 하지만 근본적인 숙취해소에는 미흡한 점이 많다. Lovers take various drinks and medicines to avoid and worry about the aftereffects of drinking, but they do not have enough to relieve the hangover.

그 동안 개발된 많은 숙취해소제들은 주로 혈중 알코올 농도만을 감소시키는데 목적을 두었기 때문에 과음시 부작용을 일으키는 주된 물질인 아세트알데히드에 의한 숙취를 효과적으로 완하시키고 해소시킬 수 있는 제제의 개발은 아직까지 미미한 상태이다. 이에 본 발명자들은 마그네슘화합물 및/또는 마그네슘염과 단삼추출물을 포함하는 조성물이 혈중 아세트알데히드 및 알코올 농도를 동시에 감소시킬 뿐만 아니라, 간세포 및 위벽세포 보호작용이 있음을 확인하여 본 발명을 완성하게 되었다.
Many of the hangovers developed in the past have been aimed at reducing blood alcohol levels only. Therefore, the development of drugs that can effectively alleviate and resolve hangovers caused by acetaldehyde, a major substance causing excessive side effects, has yet to be developed. to be. Accordingly, the present inventors have completed the present invention by confirming that the composition including magnesium compound and / or magnesium salt and salvia extract reduces blood acetaldehyde and alcohol concentration simultaneously, as well as hepatocellular and gastric parietal cell protection.

본 발명은 알코올 및 아세트알데히드 대사를 촉진하고 간세포 및 위벽세포를 보호하여, 알코올의 부작용을 최소화시킬 수 있는 숙취의 예방 및 해소용 조성물 및 복용시 숙취를 최소화 하는 우수한 효과를 갖는 기능성 주류를 제공하는 것을 목적으로 한다.
The present invention promotes alcohol and acetaldehyde metabolism and protects hepatocytes and gastric parietal cells, thereby providing a composition for the prevention and resolution of hangover that can minimize the side effects of alcohol and a functional liquor having an excellent effect of minimizing hangover when taken. For the purpose of

본 발명은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 포함하는 숙취의 예방 및 해소용 조성물, 및 기능성 주류에 관한 것이다. The present invention relates to a composition for preventing and eliminating hangovers, and functional liquor comprising one or more components selected from the group consisting of magnesium compounds and magnesium salts and salvia extract.                     

본 발명의 숙취의 예방 및 해소용 조성물, 및 기능성 주류는 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나이상의 성분을 더 포함할 수 있다.The composition for preventing and eliminating hangover of the present invention, and the functional liquor may further include one or more components selected from the group consisting of vitamin B1, methionine, L-alanine, and hawthorn fruit extract.

본 발명의 숙취의 예방 및 해소용 조성물, 및 기능성 주류에서 사용되는 마그네슘 화합물의 대표적인 예로는 산화마그네슘, 수산화마그네슘 등을 들 수 있으며; 마그네슘염의 대표적인 예로는 염화 마그네슘, 황산 마그네슘, 구연산 마그네슘, 젖산 마그네슘, 스테아릭산 마그네슘, 글루콘산 마그네슘 등을 들 수 있다. 특히, 산화마그네슘, 글루콘산 마그네슘 등은 좀 더 바람직한 효과를 나타낸다.
Representative examples of the composition for preventing and eliminating hangovers of the present invention, and magnesium compounds used in the functional liquor include magnesium oxide, magnesium hydroxide, and the like; Representative examples of magnesium salts include magnesium chloride, magnesium sulfate, magnesium citrate, magnesium lactate, magnesium stearate, magnesium gluconate and the like. In particular, magnesium oxide, magnesium gluconate, and the like exhibit more favorable effects.

본 발명에서 숙취의 예방 및 해소용 조성물이란 이러한 용도의 약제학적 제제, 식품, 음료, 식품 첨가제 등을 포함하는 개념이다.In the present invention, the composition for preventing and eliminating hangover is a concept including a pharmaceutical formulation, food, beverage, food additives and the like for such use.

본 발명의 숙취의 예방 및 해소용 조성물은 조성물에 포함된 마그네슘화합물 및/또는 마그네슘염을 마그네슘 함량으로 환산한 것을 기준으로 통상 1일 1-3회, 1-2400 mg/1회로 투여될 수 있으며, 바람직하게는 10-1000 mg/1회로 투여될 수 있다. The composition for preventing and eliminating hangover of the present invention can be administered 1-3 times a day, 1-2400 mg / 1 times based on the magnesium compound and / or magnesium salt contained in the composition in terms of magnesium content Preferably, 10-1000 mg / 1.

본 발명의 숙취의 예방 및 해소용 조성물은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분을 마그네슘 함량으로 환산하여 0.01-95 중량%로 포함하고 단삼추출물을 0.001-80중량%로 포함할 수 있다.The composition for preventing and eliminating hangover of the present invention may include 0.01-95% by weight of one or more components selected from the group consisting of magnesium compounds and magnesium salts and 0.001-80% by weight of salvia extract have.

또한, 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나이상의 성분을 더 포함하는 경우에는 0.001-80 중량%로 포함할 수 있다. In addition , if the vitamin B1, methionine, L-alanine, and the barberry fruit extract further comprises one or more components selected from the group may be included in 0.001-80% by weight.

알코올을 과도하게 섭취하면 위장장애를 일으킬 뿐만 아니라(Mach, T. Protective effect of alkalies on ethyl alcohol-damaged gastric mucosa. Folia Med. Cracov. 30(3-4):93-101,1989), 생체내 마그네슘의 배설을 촉진하여 혈중 마그네슘 농도를 감소시켜 심혈관계 질환(Chakraborti et al. Protective role of magnesium in cardiovascula diseases: a review. Mol Cell Biochem. Sep;238(1-2):163-79, 2002), 신장질환(Vamvakas et al. Acohl abuse: potential role in electrolyte disturbances and kidney diseases. Clin Nephrol. Apr:49(4)205-13, 1998) 및 신경계질환(Thomson. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. Alcohol Alchol. 2000) 등 다양한 질환을 일으키는 것으로 알려져 있다. Excessive alcohol consumption not only causes gastrointestinal disorders (Mach, T. Protective effect of alkalies on ethyl alcohol-damaged gastric mucosa.Folia Med. Cracov. 30 (3-4): 93-101,1989) Cardiovascular disease by promoting the excretion of magnesium, reducing the concentration of magnesium in the blood (Chakraborti et al. Protective role of magnesium in cardiova scula diseases: a review.Mol Cell Biochem. Sep; 238 (1-2): 163-79, 2002) (Vamvakas et al. Acohl abuse: potential role in electrolyte disturbances and kidney diseases.Clin Nephrol. Apr: 49 (4) 205-13, 1998) and nervous system diseases (Thomson. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome.Alcohol Alchol. 2000).

본발명자들은 알코올의 섭취 전후에 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분을 적당량 섭취하면, 생체내 알코올 대사에 관여하는 알코올 디히드로게나제, 아세트알데히드 디히드로게나제 등의 효소활성을 촉진하고(Thomasson et al. Alcohol and aldehyde dehydrogenase polymorphisms and alcoholism. Behavior Genetics. 23(2):131-136, 1993), 알코올에 의한 혈중 마그네슘의 손실을 보충하는 효과가 있어서 숙취의 예방 및 해소에 효과가 있음을 발견하였다. The present inventors, by ingesting an appropriate amount of one or more components selected from the group consisting of magnesium compounds and magnesium salts before and after ingestion of alcohol, may induce enzyme activities such as alcohol dehydrogenase and acetaldehyde dehydrogenase, which are involved in alcohol metabolism in vivo. (Thomasson et al. Alcohol and aldehyde dehydrogenase polymorphisms and alcoholism.Behavioral Genetics. 23 (2): 131-136, 1993) and supplement the loss of blood magnesium by alcohol, which is effective in preventing and eliminating hangovers. Was found.

더나아가서, 알코올의 섭취 전후에 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 함께 섭취하면 이들 성 분의 시너지 효과에 의해서 마그네슘류만을 단독으로 섭취했을 때 보다 매우 우수한 숙취의 예방 및 해소효과가 나타남을 실험을 통하여 확인하였다.
Furthermore, by ingesting at least one ingredient selected from the group consisting of magnesium compounds and magnesium salts before and after the alcohol intake and the salvia extract, the synergy of these ingredients prevents the better hangover than when magnesium alone is ingested. And it was confirmed through experiments that the effect of resolving.

본 발명에서 사용된 단삼(Salviae miltiorrhizae Bunge)은 다년생 본초인 단삼의 뿌리로써 맛은 쓰며, 약간 찬 성질이 있는 무독성인 약재로 알려져 있으며, 단삼의 성분은 단시오닌(tanshionine), 밀티오논(miltionone), 살비아노릭산(salvianolic acid) 등이 밝혀졌고, 약리작용으로는 뇌허혈보호작용, 항고혈압작용, cisplatin에 의해 유도된 급성신장장애의 보호작용, 간섬유화 억제작용, IgE에 의한 알러지 억제작용, 암세포증식 억제작용 등이 보고되었다. Salviae used in the present invention ( Salviae miltiorrhizae Bunge) is the root of the perennial herb, the taste is bitter, known as a non-toxic medicine with a slightly cold nature, the components of the dansam is tanshionine (tanshionine), millionone ( miltionone), salvianolic acid, etc., and pharmacological actions include cerebral ischemic action, antihypertensive action, cisplatin-induced acute renal impairment, hepatic fibrosis inhibitory action, and allergy suppression effect by IgE. , Cancer cell proliferation inhibitory effect has been reported.

본 발명에 추가하여 첨가될 수 있는 메치오닌은 체내에서 활성형인 아데노실메치오닌(adenosylmethionine)으로 변화되어 레시친(lecithin)의 구성성분인 코린(choline)을 합성할 수 있도록 코린에 메칠(methyl)기를 도입시켜주는 것을 도와준다. 이로써 메치오닌은 지방간을 억제하는 간 보호효과가 있다. 또한, L-alanine은 NAD의 재생을 촉진시켜 알코올디하이드로게나제를 활성화시킴으로 알코올의 분해를 증가시킨다. 헛개나무는 지구자나무, 호깨나무 또는 허래깨나무라고도 하며 술을 지나치게 마셔서 중독된 것을 치료하는 데 헛개나무를 달여서 복용한다는 내용은 성혜방 및 진남본초 등 옛 의학서적에 많이 소개되어 있다. 헛개나무는 알코올 분해 효과가 탁월하여 쥐에 투여하면 알코올 농도를 4시간 후에 50% 이상 감소시키며, 간 보호효과가 있음이 보고되었다.
In addition to the present invention, methionine can be added to the active adenosylmethionine (adenosylmethionine) in the body by introducing a methyl group to the choline (methyl) to synthesize the choline (choline) component of lecithin Help to give As a result, methionine has a liver protective effect of inhibiting fatty liver. In addition, L-alanine promotes the regeneration of NAD and activates alcohol dehydrogenase, thereby increasing the decomposition of alcohol. The barn tree is also known as earth tree, sesame tree or barberry. The use of the barn tree in the treatment of addiction by drinking too much alcohol is introduced in old medical books such as Seonghyebang and Jinnam Herb. It has been reported that the bark tree has an excellent alcohol degrading effect, and when administered to rats, alcohol concentration is reduced by 50% or more after 4 hours, and has a liver protection effect.

본 발명의 숙취의 예방 및 해소용 조성물 중에서 이러한 용도의 약제학적 제제는 약제학적으로 허용가능한 담체, 부형제 및/또는 첨가제를 포함하는 경우에 다양한 형태로 제제화될 수 있다. 즉, 본 발명에 따른 조성물은 통상의 정제, 캅셀제, 액제, 산제 등의 경구제형, 주사제, 경피투여제제 등의 비경구 제형의 형태로 제제화될 수 있다. In the compositions for the prevention and resolution of hangovers of the present invention, pharmaceutical preparations for this use can be formulated in a variety of forms when they include pharmaceutically acceptable carriers, excipients and / or additives. That is, the composition according to the present invention can be formulated in the form of parenteral formulations such as oral formulations, injections, transdermal administrations, etc., such as conventional tablets, capsules, solutions, powders.

본 발명의 숙취의 예방 및 해소용 조성물 중에서 이러한 용도의 식품 조성물은 다양한 식품류에 적용될 수 있다. 예컨데, 음료, 차, 국, 건강보조 식품류 등을 들 수 있다.In the composition for preventing and eliminating hangover of the present invention, the food composition for this use can be applied to various foods. For example, drinks, tea, soups, health supplements and the like.

또한, 본 발명의 숙취의 예방 및 해소용 조성물은 이러한 용도의 식품 첨가제 형태로도 이용될 수 있다. 예컨데, 본 발명의 조성물을 첨가제 형태로 제조하여 각종 식품에 첨가하여 이용할 수 있다.
In addition, the composition for preventing and eliminating hangover of the present invention can also be used in the form of food additives for this purpose. For example, the composition of the present invention may be prepared in an additive form and added to various foods.

본 발명에 있어서, 또 하나의 용도인 기능성 주류 조성물은 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택되는 하나 이상의 성분을 마그네슘 함량으로 환산하여 0.01-100 g/L로 포함하고 단삼추출물을 0.001-100 g/L로 포함할 수 있다. 이러한 함량은 주류의 알코올 농도에 따라 적절히 조절될 수 있다.In the present invention, the functional liquor composition, which is another use, includes 0.01-100 g / L in terms of magnesium content of one or more components selected from the group consisting of magnesium compounds and magnesium salts and 0.001-100 g of salvia extract. Can be included with / L. This content can be appropriately adjusted according to the alcohol concentration of the liquor.

또한, 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나이상의 성분을 더 포함하는 경우에는 0.001-100 g/L 중량%로 포함할 수 있다. In addition , in the case of further comprising at least one component selected from the group consisting of vitamin B1, methionine, L-alanine and hollyhock extract 0.001-100 g / L wt%.

상기에서 기능성 주류란 음주 후에 발생하는 숙취를 최소화한 주류를 의미한 다. Functional liquor in the above means a liquor with a minimum hangover that occurs after drinking.

이하에서는 본 발명을 실시예 및 실험예를 통하여 설명하고자 한다. 그러나 본 발명의 내용이 다음 실험예 한정되는 것은 아니다.
Hereinafter, the present invention will be described through Examples and Experimental Examples. However, the content of the present invention is not limited to the following experimental examples.

실시예 1 : 단삼 추출물의 제조Example 1 Preparation of Salvia Extract

단삼 1kg 70% 에탄올 3L로 50℃에서 24시간 추출하였다. 추출물을 여과하고, 잔재 생약을 다시 70% 에탄올 3L로 3회 반복하여 추출한 후, 추출액을 혼합하였다. 감압농축한 후 동결건조하여 단삼추출물 216 g을 얻었다.
1 kg 70% ethanol 3L ethanol was extracted for 24 hours at 50 ℃. The extract was filtered, and the residual crude was extracted three times with 3 L of 70% ethanol again, and the extract was mixed. Concentrated under reduced pressure and lyophilized to obtain 216 g of Salvia extract.

실시예 2 : 기능성 주류의 제조Example 2 Preparation of Functional Liquor

글루콘산 마그네슘 60 g과 단삼추출물 6g을 멸균된 증류수 1,000 ml에 용해한 후 40% 에탄올과 1:1의 비율로 혼합하여 20%(v/v) 에탄올을 제조하였다.
60 g of magnesium gluconate and 6 g of salvia extract were dissolved in 1,000 ml of sterilized distilled water, and then mixed with 40% ethanol at a ratio of 1: 1 to prepare 20% (v / v) ethanol.

실험예 1: 마그네슘 화합물 및/또는 마그네슘염과 단삼추출물의 조성물이 혈중 알콜 및 아세트 알데하이드 농도에 미치는 영향 Experimental Example 1: Effect of Magnesium Compound and / or Magnesium Salt and Salmon Extract on Composition of Blood Alcohol and Acetaldehyde

(1) 실험방법(1) Experimental method

체중 200-250g의 수컷 흰쥐(Sprague-Dawley) 6마리를 각 한 군으로 나누어 실험에 사용하였다. 동물실험군은 대조군으로서 알코올 투여군, 마그네슘 화합물 및/또는 마그네슘염을 첨가한 알코올 투여군, 단삼추출물을 첨가한 알코올 투여군, 마그네슘 화합물 및/또는 마그네슘염과 단삼추출물을 혼합하여 첨가한 알코올 투여군 및 동일한 용도로 판매되고 있는 제품(RU-21) 투여군으로 구성되었다. Six male rats (Sprague-Dawley) weighing 200-250 g were divided into one group and used for the experiment. As the control group, the animal test group was the alcohol-administered group, the alcohol-administered group with magnesium compound and / or magnesium salt, the alcohol-administered group with salviae extract, the alcohol-administered group with mixed magnesium compound and / or magnesium salt and salviae extract and the same use. It consisted of the product (RU-21) administration group on sale.

알코올 투여군에는 40% 에탄올을 2g/kg으로 경구투여하였으며;The alcohol group was orally administered with 40% ethanol at 2 g / kg;

마그네슘 화합물 및/또는 마그네슘염을 첨가한 알코올 투여군은 다음의 용량을(산화마그네슘 2, 5, 10 mg/kg; 글루콘산 마그네슘 20 mg/kg; 산화마그네슘 10 mg/kg 및 글루콘산마그네슘 10 mg/kg의 혼합) 각각 40% 에탄올에 혼합하여 경구투여하였으며,The alcohol-administered group to which the magnesium compound and / or magnesium salt was added may have the following doses (magnesium oxide 2, 5, 10 mg / kg; magnesium gluconate 20 mg / kg; magnesium oxide 10 mg / kg and magnesium gluconate 10 mg / kg each) and orally administered in 40% ethanol, respectively.

단삼추출물을 첨가한 알코올 투여군은 단삼추출물 2 mg/kg을 40% 에탄올에 혼합하여 경구투여하였으며,In the alcohol-administered group to which salvia extract was added, 2 mg / kg of salvia extract was mixed orally administered with 40% ethanol,

마그네슘 화합물 및/또는 마그네슘염과 단삼추출물을 혼합하여 첨가한 알코올 투여군은 다음의 용량을(산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg, 산화마그네슘 5mg/kg + 단삼추출물 2 mg/kg, 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg) 각각 40% 에탄올에 혼합하여 경구투여하였으며, 그리고The alcohol-administered group in which the magnesium compound and / or the magnesium salt and the salviae extract were mixed was added to the following doses (magnesium oxide 2 mg / kg + salvia extract 2 mg / kg, magnesium oxide 5 mg / kg + salvia extract 2 mg / kg, Magnesium oxide 10 mg / kg + salvia extract 2 mg / kg) and orally administered in 40% ethanol, respectively, and

동일한 용도로 판매되고 있는 제품(RU-21)은 20 mg/kg을 40% 에탄올에 혼합하여 경구투여하였다.The product sold for the same purpose (RU-21) was orally administered with 20 mg / kg mixed in 40% ethanol.

투여 후 2시간 후에 CO2 가스로 질식시킨 다음, 혈액을 채취하여 혈중 알콜 및 아세트알데히드 농도를 측정하였다.After 2 hours after administration, suffocated with CO 2 gas, blood was collected to measure blood alcohol and acetaldehyde concentration.

혈중 알콜 농도의 측정은 기체크로마토그라피로 측정하였으며, 아세트알데히드 측정은 HPLC를 아용하여 측정하였다. 혈중 아세트알데히드 농도 측정은 혈액 1ml에 3.6M HCl에 용해시킨 0.01M 디니트로페닐히드라진(dinitrophenylhydrazine, DNPH) 1ml를 첨가하여 30분 동안 실온에서 잘 혼합한 후 20 ml 펜탄(pentane)을 첨가하여 혼합한 다음 3,500rpm에서 20분간 원심분리하였다. 펜탄층을 10ml 증류수로 3회 세척한 다음 원심분리하고 펜탄층에 무수황산나트륨(Na2SO4 anhydrous)을 약간 넣어 혼합한 후 원심분리하여 펜탄층을 분리하여 증발기(evaporator)로 농축하였다. 0.5ml 아세토니트릴(acetonitrile)과 증류수를 1:1로 혼합한 용매로 HPLC로 정량하였다. HPLC의 컬럼은 Novapak C18(Waters Co.)을 사용하였으며, 전개용매는 아세토니트릴과 증류수를 1:1로 혼합하여 사용하였다. 아세트알데히드의 체류시간(retention time)은 4.95분 이었다.
Blood alcohol concentration was measured by gas chromatography, and acetaldehyde was measured by HPLC. Blood acetaldehyde concentration was measured by adding 1 ml of 0.01 M dinitrophenylhydrazine (DNPH) dissolved in 3.6 M HCl to 1 ml of blood, mixing at room temperature for 30 minutes, and then adding 20 ml pentane. Then centrifuged for 20 minutes at 3,500rpm. The pentane layer was washed three times with 10 ml of distilled water, followed by centrifugation and mixed with a small amount of anhydrous sodium sulfate (Na 2 SO 4 anhydrous) in the pentane layer, followed by centrifugation to separate the pentane layer and concentrated by an evaporator. 0.5 ml of acetonitrile and distilled water were quantified by HPLC with a solvent mixed 1: 1. HPLC column was used Novapak C18 (Waters Co.), the developing solvent was a mixture of acetonitrile and distilled water in a 1: 1. The retention time of acetaldehyde was 4.95 minutes.

(2) 실험결과(2) Experiment result

도 1에 나타낸 바와 같이, 실험군 중에서 산화마그네슘 10 mg/kg + 단삼추출물 2mg/kg 투여군 및 글루콘산 마그네슘 20 mg/kg 투여군에서 혈중 알코올 농도가 가장 현저히 감소되었다. 산화마그네슘 10 mg/kg + 단삼추출물 2mg/kg 투여군은 글루콘산 마그네슘 20 mg투여군과 비교하여, 효과면에서 비슷하나 제조상 총량적으로 훨씬 수월하다. 더불어, 기존의 숙취해소제로 개발된 RU-21 (20 mg/kg)투여군에서는 혈중 알콜농도가 대조군에 비해 유의한 차이가 없었다.
As shown in FIG. 1, blood alcohol concentrations of the magnesium oxide 10 mg / kg + salvia extract 2 mg / kg and the magnesium gluconate 20 mg / kg were most significantly reduced among the experimental groups. Magnesium oxide 10 mg / kg + Salviae extract 2 mg / kg administration group is similar in effect compared to the magnesium gluconate 20 mg administration group, but is much easier to manufacture in total. In addition, in the RU-21 (20 mg / kg) administration group developed as a conventional hangover relievers, there was no significant difference in blood alcohol concentration compared to the control group.

실험예 2: 산화마그네슘염과 단삼추출물의 조성물이 혈중 알콜 농도 및 아세트 알 데하이드 농도에 미치는 영향Experimental Example 2: Effect of the composition of magnesium oxide salt and salvia extract on blood alcohol concentration and acetaldehyde concentration

(1) 실험방법 (1) Experimental method

대조군과 산화마그네슘염 및 단삼추출물(산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg (M1), 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M2))을 첨가한 알코올 투여군에 대하여만 실험을 실시하고, 투여 후 각각 1, 2, 4시간 후에 CO2 가스로 질식시킨 다음, 혈액을 채취하여 혈중 알콜 및 아세트알데히드 농도를 측정한 것을 제외하고는 실험예 1과 동일하게 실험하였다.
For the control group and the alcohol-administered group to which magnesium oxide salt and salvia extract (magnesium oxide 2 mg / kg + salvia extract 2 mg / kg (M1), magnesium oxide 10 mg / kg + salvia extract 2 mg / kg (M2)) were added. Only the experiment was carried out, and after choking with CO 2 gas after 1, 2 and 4 hours after administration, respectively, the experiment was performed in the same manner as in Experiment 1 except that the blood alcohol and acetaldehyde concentrations were measured.

(2) 실험결과(2) Experiment result

도 2에서 볼 수 있는 바와 같이, 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M2)을 첨가한 알코올 투여군에서 2시간 대부터 혈중 알콜농도가 현저히 감소되었으나, 산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg(M1)을 첨가한 알코올 투여군은 대조군인 알코올 투여군에 비해 유의한 차이가 없었다. As can be seen in Figure 2, in the alcohol-administered group to which magnesium oxide 10 mg / kg + salvia extract 2 mg / kg (M2) was added, the blood alcohol concentration was significantly reduced from 2 hours, magnesium oxide 2 mg / kg + There was no significant difference in the alcohol-administered group with 2 mg / kg (M1) of salvia extract compared to the alcohol-administered group.

또한, 도 3에서 볼 수 있는 바와 같이, 산화마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M2)을 첨가한 알코올 투여군에서는 1시간 대부터 혈중 아세트 알데하이드 농도가 현저히 감소되었으나, 산화마그네슘 2 mg/kg + 단삼추출물 2 mg/kg(M1)을 첨가한 알코올 투여군은 대조군인 알코올 투여군에 비해 유의한 차이가 없었다.
In addition, as shown in FIG. 3, in the alcohol-administered group to which magnesium oxide 10 mg / kg + salvia extract 2 mg / kg (M2) was added, blood acetaldehyde concentration was significantly decreased from 1 hour, but magnesium oxide 2 mg There was no significant difference in the alcohol-administered group with / kg + 2 mg / kg (M1) of salvia extract compared to the alcohol-administered group.

실험예 3. 글루콘산 마그네슘과 단삼추출물의 조성물이 혈중 알콜 농도에 미치는 영향Experimental Example 3. Effect of the composition of magnesium gluconate and salvia extract on blood alcohol concentration

(1) 실험방법 (1) Experimental method

대조군과 글루콘산 마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M)을 첨가한 알코올 투여군에 대하여만 실험을 실시하고, 투여 후 각각 1, 2, 4시간 후에 CO2 가스로 질식시킨 다음, 혈액을 채취하여 혈중 알콜 및 아세트알데히드 농도를 측정한 것을 제외하고는 실험예 1과 동일하게 실험하였다.
Only the control group and the alcohol-administered group to which 10 mg / kg magnesium gluconate + 2 mg / kg (M) of salvia extract were added to the test group were suffocated with CO 2 gas after 1, 2 and 4 hours, respectively. Blood was collected and tested in the same manner as in Experiment 1 except that blood alcohol and acetaldehyde concentrations were measured.

(2) 실험결과(2) Experiment result

도 4에서 볼 수 있는 바와 같이, 글루콘산 마그네슘 10 mg/kg + 단삼추출물 2 mg/kg(M)을 첨가한 알코올 투여군에서 1시간 대부터 혈중 알코올 농도가 현저히 감소되었다.
As can be seen in Figure 4, in the alcohol administration group to which magnesium magnesium gluconate 10 mg / kg + 2 mg / kg (M) was added to the alcohol concentration of blood significantly decreased from 1 hour.

본 발명은 알코올 및 아세트알데히드 대사를 촉진하고 간세포 및 위벽세포를 보호하여, 알코올의 부작용을 최소화시킬 수 있는 숙취의 예방 및 해소용 조성물 및 복용시의 숙취를 최소화 하는 우수한 효과를 갖는 기능성 주류를 제공한다.
The present invention promotes alcohol and acetaldehyde metabolism and protects hepatocytes and gastric parietal cells, thereby providing a composition for preventing and eliminating hangovers that can minimize side effects of alcohol and a functional liquor having an excellent effect of minimizing hangovers when taken. do.

Claims (12)

마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 포함하는 숙취의 예방 및 해소용 조성물.Magnesium compound and magnesium salt composition for the prevention and resolution of hangover comprising one or more components selected from the group consisting of salviaeul extract. 제1항에 있어서, 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나 이상의 성분을을 더 포함하는 것을 특징으로 하는 숙취의 예방 및 해소용 조성물.According to claim 1, Vitamin B1, methionine, L-alanine, and the composition of the hangover fruit further comprises at least one component selected from the group consisting of a hangover fruit. 제1항에 있어서, 조성물에 포함된 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분을 마그네슘 함량으로 환산한 것을 기준으로 통상 1일 1-3회, 1-2400 mg/1회로 투여하는 것을 특징으로 하는 숙취의 예방 및 해소용 조성물.The method of claim 1, wherein the administration of 1-2400 mg / 1 times, usually 1-3 times a day, based on the magnesium content of one or more components selected from the group consisting of magnesium compounds and magnesium salts A composition for preventing and eliminating hangovers, characterized by the above. 제1항에 있어서, 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분을 마그네슘 함량으로 환산하여 0.01-95 중량%로 포함하고, 단삼추출물을 0.001-80중량%로 포함하는 것을 특징으로 하는 숙취의 예방 및 해소용 조성물.The hangover according to claim 1, comprising at least 0.01-95% by weight of at least one component selected from the group consisting of magnesium compounds and magnesium salts in terms of magnesium content, and 0.001-80% by weight of Salvia extract. Composition for the prevention and remedy. 제2항에 있어서, 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나이상의 성분을 0.001-80 중량%로 포함하는 것을 특징으로 하는 숙취의 예방 및 해소용 조성물.According to claim 2, Vitamin B1, methionine, L-alanine and the composition of the hangberry fruit extract for preventing and eliminating hangover, characterized in that it comprises 0.001-80% by weight of one or more components. 제1항에 있어서, 마그네슘화합물은 산화마그네슘과 수산화마그네슘 중에서 선택되고, 마그네슘염은 염화마그네슘, 황산마그네슘, 구연산마그네슘, 젖산마그네슘, 스테아릭산마그네슘 및 글루콘산마그네슘으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 숙취의 예방 및 해소용 조성물.The magnesium compound is selected from magnesium oxide and magnesium hydroxide, and the magnesium salt is selected from the group consisting of magnesium chloride, magnesium sulfate, magnesium citrate, magnesium lactate, magnesium stearate and magnesium gluconate. Composition for preventing and eliminating hangovers. 제1항에 있어서, 약제학적 제제, 식품, 음료 또는 식품 첨가제 형태로 제조되는 것을 특징으로 하는 숙취의 예방 및 해소용 조성물. The method for preventing and alleviating hangovers according to claim 1, which is prepared in the form of a pharmaceutical preparation, food, beverage or food additive. 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택된 하나 이상의 성분과 단삼추출물을 포함하는 기능성 주류.Functional liquor comprising one or more components selected from the group consisting of magnesium compounds and magnesium salts and salvia extract. 제8항에 있어서, 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나 이상의 성분을 더 포함하는 것을 특징으로 하는 기능성 주류.The functional liquor according to claim 8, further comprising at least one component selected from the group consisting of vitamin B1, methionine, L-alanine and hollyhock extract. 제8항에 있어서, 마그네슘 화합물 및 마그네슘염으로 이루어진 군으로부터 선택되는 하나 이상의 성분을 마그네슘 함량으로 환산하여 0.01-100 mg/L로 포함하 고 단삼추출물을 0.001-100g/L 중량%로 포함하는 것을 특징으로 하는 기능성 주류.The method according to claim 8, wherein the magnesium compound and one or more components selected from the group consisting of magnesium salts in terms of magnesium content containing 0.01-100 mg / L and containing the salviae extract in 0.001-100g / L weight% Functional liquor characterized by. 제9항에 있어서, 비타민 B1, 메치오닌, L-alanine 및 헛개나무열매추출물로 이루어진 군에서 선택된 하나이상의 성분을 0.001-100g/L 중량%로 포함하는 것을 특징으로 하는 기능성 주류. 10. The functional liquor according to claim 9, which comprises at least 0.001-100 g / L wt% of at least one component selected from the group consisting of vitamin B1, methionine, L-alanine and hollyhock extract. 제8항에 있어서, 마그네슘화합물은 산화마그네슘과 수산화마그네슘 중에서 선택되고, 마그네슘염은 염화마그네슘, 황산마그네슘, 구연산마그네슘, 젖산마그네슘, 스테아릭산마그네슘 및 글루콘산마그네슘으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 위궤양의 예방 및 치료용 조성물.The magnesium compound is selected from magnesium oxide and magnesium hydroxide, and the magnesium salt is selected from the group consisting of magnesium chloride, magnesium sulfate, magnesium citrate, magnesium lactate, magnesium stearate and magnesium gluconate. Composition for the prevention and treatment of gastric ulcers.
KR1020040082247A 2004-10-14 2004-10-14 Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor Ceased KR20060033247A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020040082247A KR20060033247A (en) 2004-10-14 2004-10-14 Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020040082247A KR20060033247A (en) 2004-10-14 2004-10-14 Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor

Publications (1)

Publication Number Publication Date
KR20060033247A true KR20060033247A (en) 2006-04-19

Family

ID=37142392

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020040082247A Ceased KR20060033247A (en) 2004-10-14 2004-10-14 Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor

Country Status (1)

Country Link
KR (1) KR20060033247A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580046A (en) * 2012-03-23 2012-07-18 南宁市品迪生物工程有限公司 Zhuang ethnic group medical recipe for preventing alcoholism and sobering up

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580046A (en) * 2012-03-23 2012-07-18 南宁市品迪生物工程有限公司 Zhuang ethnic group medical recipe for preventing alcoholism and sobering up

Similar Documents

Publication Publication Date Title
WO2002102362A1 (en) Dietetic preparation and use of an alpha-hydroxy carboxylic acid (citric acid for the treatment of obesity
JP5275251B2 (en) Composition comprising an extract of a combined herb for preventing and treating liver disease
KR100877600B1 (en) Pharmaceutical composition for the prevention and treatment of alcoholic fatty liver and fatty hepatitis containing metadoxin and garlic oil as active ingredients
KR100697056B1 (en) Composition for the prevention and treatment of liver disease, including liquirithiinin as an active ingredient
WO2014010656A1 (en) Superior blood alcohol concentration reduction accelerating agent
US5464620A (en) Pharmaceutical composition for treating gastrointestinal disease
WO2006119038A1 (en) Compositions and methods for controlling glucose uptake
JP4422685B2 (en) Use of pinitol or cayloisitol for liver protection
EP4181693B1 (en) Nutritional supplement for use in a method of protection of the liver from the effects of the use of methotrexate as a chemotherapeutic drug, comprising dihydromyricetin, choline and one or more vitamins with antioxidant activity
JP4233645B2 (en) Lipase inhibitor
KR20060033247A (en) Composition for preventing and eliminating hangover, including magnesium compound and / or magnesium salt and salviae, and functional liquor
TWI334783B (en) Pharmaceutical composition for facilitating the reduction of blood-alcohol concentration after alcohol intake
JP5422370B2 (en) Oral liquid composition
JP6835396B2 (en) Composition for reducing blood glucose concentration, reducing blood hemoglobin A1c amount, or increasing blood HDL-cholesterol level
KR20050049416A (en) Composition for prevention and relief of alcoholic hangover, and alcoholic liquors containing magnesium compound and/or magnesium salt
TWI871016B (en) Use of magau extract for preparing a composition for improving sleep and resisting depression
KR20020004193A (en) Composition for liver protection containing inhibitors of alcohol absorption
TWI732147B (en) Extracts and compositions for inhibiting acetylcholinesterase
TW202513087A (en) Composition for enhancing or improving kidney function
US20080279968A1 (en) Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids
JPH1072460A (en) Prevention of neuronal cell death, therapeutic agent for improving ischemic disease and method for producing the same
HK40064821A (en) Composition for lowering blood glucose level, reducing blood hemoglobin a1c content, or increasing blood hdl-cholesterol content
KR101322721B1 (en) Anti-obesity composition containing the Platycodon grandiflorum fraction from the Platycodon grandiflorum roots with high purity platycosides
KR100846441B1 (en) Pharmaceutical Compositions, Health Food Compositions, Cosmetic Compositions, and Panasonic X Nuclear Receptor Inhibitor Compositions Containing Sterol Derivatives
JP3088111B2 (en) Saponin-containing alcohol absorption inhibitor

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20041014

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090902

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20041014

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110412

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110622

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110412

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I